Literature DB >> 15890574

Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.

Eugene H Huang1, Susan L Tucker, Eric A Strom, Marsha D McNeese, Henry M Kuerer, Gabriel N Hortobagyi, Aman U Buzdar, Vicente Valero, George H Perkins, Naomi R Schechter, Kelly K Hunt, Aysegul A Sahin, Thomas A Buchholz.   

Abstract

PURPOSE: To identify the clinical and pathologic factors predictive of locoregional recurrence (LRR) after neoadjuvant chemotherapy, mastectomy, and radiotherapy. METHODS AND MATERIALS: We retrospectively reviewed the hospital records of 542 patients treated on six consecutive institutional prospective trials using neoadjuvant chemotherapy and postmastectomy radiotherapy. The clinical stage (American Joint Committee on Cancer, 1988) was Stage II in 17%, Stage IIIA in 30%, Stage IIIB in 43%, and Stage IV (ipsilateral supraclavicular disease) in 10%. All LRRs were considered events, irrespective of the timing to distant metastases.
RESULTS: The median follow-up was 70 months. The 5-year and 10-year actuarial LRR rate was 9% and 11%, respectively. The clinical factors associated with LRR included combined clinical stage, clinical T stage, ipsilateral supraclavicular nodal disease, chemotherapy response, physical examination size after chemotherapy, and no tamoxifen use (p < or = 0.04 for all factors). The pathologic predictors of LRR included the number of positive nodes, dissection of <10 nodes, multifocal/multicentric disease, lymphovascular space invasion, extracapsular extension, skin/nipple involvement, and estrogen receptor-negative disease (p <or = 0.05 for all factors). Multivariate Cox regression analysis revealed that five factors independently predicted for LRR: skin/nipple involvement, supraclavicular nodal disease, no tamoxifen use, extracapsular extension, and estrogen receptor-negative disease (hazard ratio, 2.1-2.8; p < or = 0.02 for all factors). The 10-year LRR rate was only 4% for patients with one or none of these five independent factors, 8% for those with two factors, and 28% for those with three or more factors (p < 0.0001).
CONCLUSION: Although the long-term rate of LRR after neoadjuvant chemotherapy, mastectomy, and radiotherapy is low, we identified a number of factors that correlated independently with greater rates of LRR. Patients with three or more of these factors may benefit from research protocols investigating alternative treatment strategies.

Entities:  

Mesh:

Year:  2005        PMID: 15890574     DOI: 10.1016/j.ijrobp.2004.09.056

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

Review 1.  Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data.

Authors:  Amar U Kishan; Susan A McCloskey
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

2.  Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Aziz Cengiz; Hüseyin Altınyollar
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

Review 3.  Molecular Subtypes and Local-Regional Control of Breast Cancer.

Authors:  Simona Maria Fragomeni; Andrew Sciallis; Jacqueline S Jeruss
Journal:  Surg Oncol Clin N Am       Date:  2018-01       Impact factor: 3.495

4.  Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).

Authors:  Elizabeth L Cureton; Christina Yau; Michael D Alvarado; Helen Krontiras; David W Ollila; Cheryl A Ewing; Sindy Monnier; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2014-05-01       Impact factor: 5.344

5.  The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.

Authors:  T Jonathan Yang; Monica Morrow; Shanu Modi; Zhigang Zhang; Kate Krause; Chun Siu; Beryl McCormick; Simon N Powell; Alice Y Ho
Journal:  Ann Surg Oncol       Date:  2015-07-01       Impact factor: 5.344

6.  Breast cancer local recurrence under the form of inflammatory carcinoma, treated with concurrent radiation and chemotherapy, a case report.

Authors:  Isabel Reis; Helena Pereira; Isabel Azevedo; João Conde; Isabel Bravo; Rogéria Craveiro; Deolinda Pereira
Journal:  Rep Pract Oncol Radiother       Date:  2013-10-20

7.  Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  Alberto Alvarado-Miranda; Oscar Arrieta; Carlos Gamboa-Vignolle; David Saavedra-Perez; Rafael Morales-Barrera; Enrique Bargallo-Rocha; Juan Zinser-Sierra; Victor Perez-Sanchez; Teresa Ramirez-Ugalde; Fernando Lara-Medina
Journal:  Radiat Oncol       Date:  2009-07-11       Impact factor: 3.481

8.  Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy.

Authors:  Luigi Moretti; David S Yu; Heidi Chen; David P Carbone; David H Johnson; Vicki L Keedy; Joe B Putnam; Alan B Sandler; Yu Shyr; Bo Lu
Journal:  Oncologist       Date:  2009-11-06

9.  Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy.

Authors:  Ying L Liu; Anurag Saraf; Shing M Lee; Xiaobo Zhong; Hanina Hibshoosh; Kevin Kalinsky; Eileen P Connolly
Journal:  Breast Cancer Res Treat       Date:  2016-05-25       Impact factor: 4.872

10.  DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer.

Authors:  Frederik Wenz; Elena Sperk; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Marc D Piroth; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Rainer Souchon; Christoph Fussl; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2014-08       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.